Toyoda H, et al. - Authors sought to assess the real-world virological efficacy and safety of an interferon (IFN)-free direct-acting antiviral (DAA) therapy with elbasvir (EBR) and grazoprevir (GZR) in Japanese patients chronically infected with hepatitis C virus (HCV) genotype 1. Between November 2016 and July 2017, the rate of sustained virologic response (SVR) and safety was analyzed in patients who started the EBR/GZR regimen. The present data indicated that the EBR/GZR regimen yielded high virological efficacy with acceptable safety. It was observed in the findings that patients with a history of failure to IFN-free DAA therapy or with double resistance-associated substitutions (RASs) in HCV-non-structural protein 5A (NS5A) remained difficult to treat with this regimen.